Mohammed Qatanani
Chief Tech/Sci/R&D Officer chez SCHOLAR ROCK HOLDING CORPORATION
Fortune : 3 M $ au 31/03/2024
Profil
Mohammed Qatanani is currently the Chief Scientific Officer at Scholar Rock Holding Corp.
He previously worked as the Director-Discovery Research at Alexion Pharmaceuticals, Inc. from 2015 to 2018 and as the Vice President-Program & Alliance Management at Dyne Therapeutics, Inc. from 2018 to 2021.
Dr. Qatanani completed his undergraduate and graduate degrees at the American University of Beirut and holds an MBA from Baylor College of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/02/2024 | 147 019 ( 0,19% ) | 3 M $ | 31/03/2024 |
Postes actifs de Mohammed Qatanani
| Sociétés | Poste | Début |
|---|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Chief Tech/Sci/R&D Officer | 01/09/2022 |
Anciens postes connus de Mohammed Qatanani
| Sociétés | Poste | Fin |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/09/2021 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2018 |
Formation de Mohammed Qatanani
| American University of Beirut | Graduate Degree |
| Baylor College of Medicine | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
| DYNE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
